Tarsus Pharmaceuticals (TARS) Cash & Equivalents (2019 - 2026)

Tarsus Pharmaceuticals' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $102.2 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 41.87% year-over-year to $102.2 million in Q1 2026; TTM through Mar 2026 was $102.2 million, a 41.87% decrease from a year earlier, with the FY2025 full-year figure at $183.6 million, up 93.68% from the prior year.
• Cash & Equivalents eased to $102.2 million in Q1 2026 per TARS's latest filing, from $183.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $245.4 million in Q2 2022 and bottomed at $66.0 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $175.0 million (2022), against an average of $153.1 million.
• Biggest YoY gain for Cash & Equivalents was 213.91% in 2023; the steepest drop was 62.29% in 2023.
• Year by year, Cash & Equivalents stood at $71.7 million in 2022, then jumped by 213.91% to $224.9 million in 2023, then tumbled by 57.85% to $94.8 million in 2024, then surged by 93.68% to $183.6 million in 2025, then plunged by 44.35% to $102.2 million in 2026.
• Per Business Quant, the three latest TARS Cash & Equivalents figures stand at $102.2 million (Q1 2026), $183.6 million (Q4 2025), and $112.7 million (Q3 2025).